32%), lower median PSA (88 vs. 146 µg/l) and the absence of massive bone metastases (>20 metastases: 0% vs. 32%). Most of our patients (63%), in fact, were treated with Radium-223 in an early setting as first- or second-line.
Exposure to radium over a period of many years may result in an increased risk of some types of cancer, particularly lung and bone cancer. Higher doses of radium have been shown to cause effects on the blood (anemia), eyes (cataracts), teeth (broken teeth), and bones (reduced bone growth).
Initial signs and symptoms
- Nausea and vomiting.
- Diarrhea.
- Headache.
- Fever.
- Dizziness and disorientation.
- Weakness and fatigue.
- Hair loss.
- Bloody vomit and stools from internal bleeding.
Radium 223 is a mildly radioactive form of the metal radium. It used to be called Alpharadin and now has the brand name Xofigo (pronounced zoh-fee-go). Radium 223 can shrink areas of cancer cells that have spread to the bone. This reduces symptoms, such as pain, and helps you feel more comfortable.
The most common early side effects are fatigue (feeling tired) and skin changes. Other early side effects usually are related to the area being treated, such as hair loss and mouth problems when radiation treatment is given to this area. Late side effects can take months or even years to develop.
“In fact, based on the literature reviewed, it appears that external-beam radiation therapy is a superior treatment in some cases. “When patients are treated with modern external-beam radiation therapy, the overall cure rate was 93.3% with a metastasis-free survival rate at 5 years of 96.9%.
How likely is radium to cause cancer? Exposure to high levels of radium results in an increased incidence of bone, liver, and breast cancer. The EPA and the National Academy of Sciences, Committee on Biological Effects of Ionizing Radiation, has stated that radium is a known human carcinogen.
Radium targets bone cancer cells. This is because it is similar to calcium, which is also absorbed by bone cells. The cancer cells in the bone take up radium 223 and it then releases radiation which travels a very short distance. This means that the cancer cells receive a high dose of radiation which can destroy them.
Many people worry about being in pain when they are dying. Some people do get pain if their prostate cancer presses on their nerves or makes their bones weak. But not everyone dying from prostate cancer has pain. And if you are in pain, there are things that can help to reduce and manage pain.
Xofigo is a medication used to treat prostate cancer that has spread to your bone. It can help prevent symptoms caused by the cancer in your bones.
Xofigo (radium Ra 223 dichloride) is a radiotherapeutic drug used to treat patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
Radium-223 dichloride is an alpha-particle emitting radio isotope. The drug mimics calcium and forms complexes with the bone mineral at sites of bone metastases. It then emits alpha particles, causing the destruction of DNA in nearby cells, resulting in cancer cell death in the bone.
Radium-223 has a half-life of 11.4 days. The specific activity of radium-223 is 1.9 MBq (51.4 microcurie)/ng. The six-stage-decay of radium-223 to stable lead-207 occurs via short-lived daughters, and is accompanied predominantly by alpha emissions.
Xofigo is effective in reducing tumor growth and relieving bone pain. It is well-tolerated in most patients. Dr. George noted that Xofigo doesn't have much effect on PSA or the androgen pathway.
Once prostate cancer has spread beyond the prostate, survival rates fall. For men with distant spread (metastasis) of prostate cancer, about one-third will survive for five years after diagnosis.
Origin and preparation. Although radium-223 is naturally formed in trace amounts by the decay of uranium-235, it is generally made artificially, by exposing natural radium-226 to neutrons to produce radium-227, which decays with a 42-minute half-life to actinium-227.
Xofigo is given as a 1-minute IV injection. Over the course of your therapy, you will receive 1 injection every 4 weeks until you reach a total of 6 injections.
According to the drug manufacturer, 6 cycles of treatment with radium- 223 cost $69,000.16 For comparison, docetaxel (Taxotere) costs approximately $14,500 for a course of 10 cycles plus ancillary costs; enzalutamide costs approximately $60,000 for 8 months of treatment; and a treatment course of sipuleucel-T costs
Radium-223 Therapy is a type of treatment that is used for people who have prostate cancer that has spread, or metastasised, to the bones. Its aim is to damage the cancer cells in the bone, leading to the tumours shrinking in size, or even disappearing altogether.
Radium targets bone cancer cells. The cancer cells in the bone take up radium 223 and it then releases radiation which travels a very short distance. This means that the cancer cells receive a high dose of radiation which can destroy them. And healthy cells receive only a low dose or no radiation.
Doctors can treat, but not cure, advanced prostate cancer. The goal is to slow down the cancer's spread and help you feel better. Most men with it have a high quality of life for many years. There are different kinds of treatments, including hormone therapy, immunotherapy, radiation, and chemotherapy.
Common side effects of radiation therapy include:
- Skin problems. Some people who receive radiation therapy experience dryness, itching, blistering, or peeling.
- Fatigue. Fatigue describes feeling tired or exhausted almost all the time.
- Long-term side effects.
- Head and neck.
- Chest.
- Stomach and abdomen.
- Pelvis.
Most side effects generally go away within a few weeks to 2 months of finishing treatment. But some side effects may continue after treatment is over because it takes time for healthy cells to recover from the effects of radiation therapy. Late side effects can happen months or years after treatment.
Radiotherapy is a possible treatment for rectal cancer, it is not usually used to treat bowel cancer. You may have radiotherapy to try to cure your cancer, either alone or together with surgery or chemotherapy (chemoradiation). If your cancer cannot be cured, you may have radiotherapy to relieve your symptoms.
Radium 223 is a mildly radioactive form of the metal radium. It's brand name is Xofigo (pronounced zoh-fee-go). You might have radium 223 to treat cancers in the bone that began in the prostate. Radium 223 can treat cancers in more than one area of the bone and help to reduce pain.
All isotopes of radium are highly radioactive, with the most stable isotope being radium-226, which has a half-life of 1600 years and decays into radon gas (specifically the isotope radon-222). When radium decays, ionizing radiation is a product, which can excite fluorescent chemicals and cause radioluminescence.
Radiation therapy will generally cause hair loss to the body part that is being treated. For example, if your arm were treated with radiation, you may lose any hair on your arm, but the hair on your head would not be affected. Chemotherapy drugs also can cause hair loss.
Systemic radiation therapy uses radioactive drugs (called radiopharmaceuticals or radionuclides) to treat certain types of cancer, including thyroid, bone, and prostate cancer. These are liquid drugs made up of a radioactive substance. They can be given by mouth or put into a vein; they then travel throughout the body.
Radium-223 dichloride (radium-223) is a radioactive isotope that emits low levels of alpha particle radiation. The alpha particle radiation causes double-strand breaks in DNA, killing cells.
Radiation works by making small breaks in the DNA inside cells. These breaks keep cancer cells from growing and dividing and cause them to die. Nearby normal cells can also be affected by radiation, but most recover and go back to working the way they should.
Potential side effects of external beam radiation therapy for prostate cancer may include: Frequent urination. Difficult or painful urination. Blood in the urine.
Radium-223 (223Ra, Ra-223) was discovered in 1905 by T. Godlewski, a Polish chemist from Kraków, and is historically known as actinium X, or AcX. It is an isotope of radium with an 11.4-day half-life, in contrast to the more common isotope radium-226, discovered by the Curies, which has a 1600-year half-life.
In contrast are radioactive isotopes. Caesium-137 is another example of an implantable radioactive isotope used in the treatment of uterine or vaginal cancers in conjunction with other therapies, i.e. chemotherapy. If radioactive isotopes are left inside the person they will of course continue to emit radiation.
Types of radioisotope therapy
- Iodine-131. This is the most common type of radioisotope therapy.
- Strontium-89 and Samarium-153. These radioisotopes can be used to treat some types of cancer that have spread to the bones (metastatic bone cancer).
- Radium-223.
The history of radiation therapy or radiotherapy can be traced back to experiments made soon after the discovery of x-rays (1895), when it was shown that exposure to radiation produced cutaneous burns. The use of radiation continues today as a treatment for cancer in radiation therapy.
